ARL13B

Across TCGA pan-cancer cohorts, ARL13B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARL13B data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARL13B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARL13B expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where ARL13B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.747	0.959	.045	5	view →
UCEC	DFS	Median	III,IV	0.850	0.376	.026	4	view →
HNSC	DFS	Median	IV	0.244	0.974	.038	3	view →
LSCC	OS	Median	II,III,IV	1.000	0.885	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARL13B–PDAC (OS)

Open the PDAC breakdown →